BioAge

@bioagelabs

BioAge is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases.

Richmond, CA

bioagelabs.com

Replies Reposts Media

Pinned
BioAge
@bioagelabs
Jun 16
Today, we are pleased to announce that the first participant has been dosed in QUELL-CV, our Phase 2 proof-of-concept trial of BGE-102, BioAge's oral, once-daily, brain-penetrant NLRP3 inhibitor, in patients at elevated cardiovascular risk. Inflammation is now recognized as a
globenewswire.com
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of...
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic...
3
BioAge
@bioagelabs
Sep 8
Today BioAge announced that the first participant has been dosed in QUELL-DME, our randomized, controlled Phase 2 trial of our NLRP3 inhibitor BGE-102. The trial will assess whether a once-daily oral medication can improve vision in adults with diabetic macular edema (DME). ➡️
globenewswire.com
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel...
Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary...
2
BioAge
@bioagelabs
Jul 30
"We all study the same disease." That's Harvard cardiologist Peter Libby in a @nytimes feature on inflammation. Cardiology, oncology, neurology, rheumatology: increasingly, the same underlying process — inflammation — turns up in all of them. A chronically activated
Inflammation Keeps Us Alive. It's Also Making Us Sick. (Gift Article)
From nytimes.com
2
BioAge
@bioagelabs
Jul 10
Last month, BioAge initiated QUELL-CV, a Phase 2 clinical trial evaluating our oral NLRP3 inhibitor BGE-102 in adults with obesity and elevated cardiovascular risk. A second proof-of-concept study, in diabetic macular edema, is planned to begin later this year. In a conversation
Longevity.Technology
From longevity.technology
BioAge
@bioagelabs
Jun 23
The GLP-1 era has reset what metabolic medicine can achieve… but what comes next? Today at the 2026 BIO International Convention, BioAge CBO Peng Leong, PhD, joins "Beyond GLP-1s — New Mechanisms and Modalities for Metabolic Disease," a panel we're proud to sponsor. The